1. Home
  2. IGI vs CRDL Comparison

IGI vs CRDL Comparison

Compare IGI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Investment Grade Defined Opportunity Trust Inc.

IGI

Western Asset Investment Grade Defined Opportunity Trust Inc.

N/A

Current Price

$16.18

Market Cap

98.8M

Sector

Finance

ML Signal

N/A

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$1.05

Market Cap

97.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IGI
CRDL
Founded
N/A
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
98.8M
97.3M
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
IGI
CRDL
Price
$16.18
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
20.8K
323.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.70
$0.77
52 Week High
$17.09
$1.59

Technical Indicators

Market Signals
Indicator
IGI
CRDL
Relative Strength Index (RSI) 26.53 53.59
Support Level $15.78 $1.03
Resistance Level $16.60 $1.10
Average True Range (ATR) 0.11 0.05
MACD -0.04 -0.00
Stochastic Oscillator 21.26 66.09

Price Performance

Historical Comparison
IGI
CRDL

About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.

Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: